( 42) entered their fourth year of contin...)Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR,Health

Patients with JRA who participated previously in a double-blind, randomized controlled trial of ENBREL (n=69) were eligible to enroll in this multicenter open-label extension study (n=58). Safety assessments included the incidence of serious adverse events, deaths, lymphomas, malignancies, opportunistic infections and medically important infections.

ABOUT ENBREL

ENBREL is a fully human soluble TNF receptor. ENBREL has more than 14 years of collective clinical experience.

ENBREL Indications:

-- ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more DMARDs.

-- ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with moderate to severe rheumatoid arthritis. ENBREL can be taken with methotrexate or used alone.

-- ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with psoriatic arthritis. ENBREL can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.

-- ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

-- ENBREL is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

What important information do I need to know about taking prescription Enbrel(R) (etanercept)?

ENBREL is a type of protein called a tumor necrosis factor (TNF) blocker that blocks the action of a s
'"/>